ClinicalTrials.gg

Program

HRS9432

A development code.

In Jiangsu HengRui Medicine's pipeline, Anidulafungin derivatives. Its studies are mostly in Candidemia, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Dec 21, 20231 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine10 open or runningphase 2since Dec 21, 2023Dec 21, 2023none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS9432, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2023First study: phase 2 study in Patients With Candidemia and/or Invasive CandidiasisFirst studyNCT06194201 · 61 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Anidulafungin derivatives”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06194201Patients With Candidemia and/or Invasive Candidiasis · China2CompletedNov 7, 202561

How it is read

Names in the registry

  • “HRS9432”, 1 entry

Codes read as this program: HRS9432.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.